If you have been reading about cyclic heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic peptide | Melanocortin receptor agonist family |
| Molecular weight | Approximately 1025 Da | Free base form |
| Appearance | White to off-white powder | Lyophilized product |
| Solubility | Soluble in water | Also dissolves in polar organic solvents |
| Storage temperature | -20 degrees Celsius | Dry and protected from light |
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
=== British Isles === A half and half is commonly understood to be a side dish of half chips and half rice. The term is used across the British Isles but most commonly in the north of England and Wales. A typical order might be "chicken curry half and half" or "chili con carne half and half".
== External links == The MEROPS online database for peptidases and their inhibitors: M13.001 Archived 2019-09-12 at the Wayback Machine Neprilysin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P08473 (Neprilysin) at the PDBe-KB. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Created by writer Chris Claremont, Elizabeth "Betsy" Braddock first appeared in Captain Britain #8 (December 1976), with Captain Britain #10 (December 1976) as her first cover appearance, published by the Marvel Comics' British imprint Marvel UK. In New Mutants Annual #2 (1986), Claremont integrated Betsy Braddock into the X-Men franchise. After being rescued by the New Mutants and taking up residence at their mutant-training academy, Braddock is formally invited to join the X-Men and officially adopts the codename Psylocke, becoming an enduring fixture of the team over the next three decades. In Uncanny X-Men #213 (January 1987), Psylocke battles Sabretooth, demonstrating her fighting skills by holding him at bay. In Uncanny X-Men #256 (December 1989), an amnesiac Betsy is kidnapped by the Hand, who brainwash her and physically alter her to take on an East Asian appearance. Under the name Lady Mandarin, she briefly becomes the Hand's supreme assassin. While her memories return, she retains her new appearance and skills, including the ability to manifest the focused totality of her telepathic power in the form of a “psychic knife.” The art for Psylocke's redesigned costume is by Jim Lee. In a later interview, he describes the creative process:
Division 1. Order Lepisosteiformes – the relict gars, which include extant species of gars that first appeared in the Cretaceous Division 2. Order Amiiformes – the relict bowfin, (halecomorphids), the only extant species in the order Amiiformes, which date back to the Triassic period Division 3. Division Teleostei – the stem group of Teleostei from which modern fish arose, including most of the bony fish familiar today
Prussia never had more than 320,000 men under arms at any time. In 1813–1815, the core of its army (about 100,000 men) was characterised by competence and determination, but the bulk of its forces consisted of second- and third-line troops, as well as militiamen of variable strength. Many of these troops performed reasonably well and often displayed considerable bravery but lacked the professionalism of their regular counterparts and were not as well equipped. Others were largely unfit for operations, except sieges. During the 1813 campaign, 130,000 men were used in the military operations, with 100,000 effectively participating in the main German campaign, and about 30,000 being used to besiege isolated French garrisons. Spain's armies also peaked at around 200,000 men, not including more than 50,000 guerrillas scattered over Spain. In addition the Maratha Empire, the Ottoman Empire, Italy, Naples and the Duchy of Warsaw each had more than 100,000 men under arms. Even small nations now had armies rivalling the size of the Great Powers' forces of past wars but most of these were poor quality forces only suitable for garrison duties. The size of their combat forces remained modest yet they could still provide a welcome addition to the major powers. The percentage of French troops in the Grande Armée which Napoleon led into Russia was about 50 per cent while the French allies also provided a significant contribution to the French forces in Spain.
Sources: en.wikipedia.org
==== Antibodies ==== Two monoclonal antibodies have been approved to target amyloid beta – donanemab and lecanemab – but as of 2025, their role in treatment is uncertain because of side effects, questions about efficacy, and cost. Lecanemab is approved in the US, including a boxed warning about amyloid-related imaging abnormalities. A 2026 meta-analysis found that anti-amyloid antibodies have no effect in the treatment of Alzheimer's disease. A 2026 Cochrane review found no effect or at best small effect. Anti-amyloid antibodies may cause harmful adverse effects and have been shown to slow disease progression only in individuals with "early and mild AD, and cognitive benefits were often marginal."
== Mosaic Diagnostics, formerly Great Plains Laboratory == William Shaw's laboratory is known for performing nonstandard tests which have been used by alternative medicine practitioners to support discredited diagnoses. Great Plains Laboratory's urine mycotoxin test is not validated nor recommended for diagnosing any condition. In May 2020, early in the COVID-19 pandemic, Great Plains marketed unproven antibody tests.
== Motorsport and racing scandals == 1994 Formula One cheating controversy – a number of allegations of cheating were thrown during the 1994 Formula One season, particularly to the Benetton team. 2007 NASCAR Gatorade Duel scandal – three various incidents related to the Gatorade Duel. 2007 Formula One espionage controversy, commonly known as Spygate – an incident in which Scuderia Ferrari mechanic Nigel Stepney passed on a secret document to Mike Coughlan of McLaren. 2008 race fixing controversy, also known as Crashgate – it was surrounded by allegations in Formula One that driver Nelson Piquet Jr. deliberately crashed in the 2008 Singapore Grand Prix to help his Renault teammate Fernando Alonso win. Felipe Massa is pursuing legal action against Formula One Management, the FIA and Bernie Ecclestone for a sum of £64m over Crashgate as he believes the FIA should have voided all points awarded in the Singapore Grand Prix, which would have led to him being 2008 World Champion. A High Court of justice in London has ruled that the case can now go to trial. 2013 Federated Auto Parts 400 – in the final Sprint Cup race, before the field was set for the 2013 Chase for the Sprint Cup, three teams—Michael Waltrip Racing, Penske Racing and Front Row Motorsports—were found to have extensively manipulated the race finish in an attempt to secure Chase places for MWR driver Martin Truex Jr. and Penske driver Joey Logano.
On 17 May 2022, militias attacked a civilian helicopter that was flying over the Rio area with rifles. No injuries were recorded but the helicopter suffered slight damage. On 20 August of the same year, Delson Lima Neto, brother of one of the leader of the militias, Tandera Danilo Dias Lima, was killed alongside 3 paramilitaries soldiers by the Polícia Militar on Nova Iguaçu, in Baixada Fluminense, after his death the Comando Vermelho conquered the favela of Grão-Pará, in Nova Iguaçu. After the raid, on 23 August, the police found and seized an improvised fighting vehicle (similar to a Caveirão) used by the militias to fight against Comando Vermelho in Nova Iguaçu. According to law student Carlos Gilberto Martins Junior of Brazil in 2023, with emphasis on the State of Rio de Janeiro, there has been an arbitrary use of these powers and attributions, conferred on police institutions, to satisfy the patrimonial aspirations of some of its agents, through territorial domination and violence, to the detriment of the peripheral communities and under the pretext of saving them from the "greater evil" represented by drug trafficking, corroborating the emergence of criminals organizations what conventionally called the "militia". On 6 May 2021, at least 29 people were killed in a shootout between gangsters of Comando Vermelho and police. On May 24 2022, the BOPE raided the Vila Cruzeiro favela in Penha Complex, killing 26 people between civilians and gangsters of Comando Vermelho.
Sources: en.wikipedia.org
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.
It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.
Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.